Clinical Research Directory

Inclusion Criteria: 1. Males and females; age ≥18 years at the time of enrollment 2. Underwent curative-intent CRS/HIPEC at MD Anderson for gastrointestinal malignancies, including colorectal cancers, appendiceal cancers, and peritoneal mesothelioma between March 1, 2016, and June 30, 2025 3. Had a complete cytoreduction with a completeness of cytoreduction score (CC) of 0 or 1 4. Currently alive and at least 6 months disease-free post-CRS/HIPEC, based on clinical documentation and follow-up imaging 5. English-speaking 6. Capable of completing an electronic survey (via REDCap) 7. Provides informed consent by proceeding to survey commencement Exclusion Criteria: * 1\. Evidence of recurrent or active malignancy at time of chart review 2. Underwent CRS/HIPEC for non-malignant conditions (e.g., multicystic mesothelioma, well-differentiated papillary mesothelioma) 3. Underwent palliative-intent surgery or had an incomplete cytoreduction (CC-2 or CC-3) 4. Did not receive HIPEC (CRS only) 5. Received HIPEC on a clinical trial 6. Significant cognitive impairment limiting ability to provide informed consent or complete the survey 7. Non-English-speaking (due to lack of validated translations for study instruments) 8. No valid contact information or no access to electronic communication (e.g., participant portal or email)